Australia's most trusted source of pharma news
Friday, 22 February 2019
Lost Your Access?
New Takeda boss brings $10m
A final PBS win as Shire boss moves to merged business.
Specialty drugs lift Mayne
But investors dissatisfied anyway.
'Unmotivated' pharmas revealed?
Which companies fell outside the listing norm in 2017-18?
New pan-tumour class emerges
Three potential contenders on the horizon.
Health holds pathways webinar
Industry, consumers, clinicians invited to tune in.
Playing PBS 'deal or no deal'
Winning this high-stakes game requires a lot of 'motivation'.
PBS stoush set for tonight
Politically charged atmosphere in Senate Estimates.
Amgen names interim boss
Local exec steps in as My Linh Kha fills Chinese gap.
Uptake drivers fail to bite
PBS data reveal the dismal impact of biosimilars.
Aust HCV 'Netflix' deal exposed
How PBS cap saved govt multi-billions.
Ward6 lands big pharmas
Novartis, Sanofi, Pfizer partner with healthcare agency.
Battle heats up for Hunt's seat
Labor tipped to run high-profile ABC journalist.
BI inhaler wins PBS boost
Spiriva Respimat expands into paediatric asthma from March.
MA board gets two new MDs
Biogen, MSD bosses to fill vacancies until October.
Labor targets listing delays
Attacks Hunt's PBS listing record in Senate Estimates.
AbbVie advances RA drug
Uses priority review voucher for upadacitinib.
Top of the Hill
Power of a patient story
Why a story told well is pharma's most valuable message.
AZ's new diabetes dose
Extended-release yet to be PBS listed.
Events & Conferences
© 2003 - 2019 Lush Media
Pharma in Focus
Jolly Good Design